Download PDF
CC BY-NC-ND 4.0 · Geburtshilfe Frauenheilkd 2018; 78(10): 923-926
DOI: 10.1055/a-0658-1918
GebFra Science
Statement/Stellungnahme
Georg Thieme Verlag KG Stuttgart · New York

Statement of the Uterus Committee of the Gynaecological Oncology Working Group (AGO) on the PORTEC-3 study

Article in several languages: English | deutsch for the Uterus Committee of the AGO
Günther Emons
1   Universitätsmedizin Göttingen, Göttingen, Germany
,
Clemens Tempfer
2   Ruhr Universität Bochum, Bochum, Germany
,
Marco Johannes Battista
3   Universitätsklinikum Mainz, Mainz, Germany
,
Alexander Mustea
4   Universitätsmedizin Greifswald, Greifswald, Germany
,
Dirk Vordermark
5   Universitätsklinik Halle (Saale), Halle (Saale), Germany
› Author Affiliations
Further Information

Publication History

received 10 July 2018

accepted 12 July 2018

Publication Date:
19 October 2018 (online)

Also available at
   Permissions and Reprints

Abstract

The data on the adjuvant therapy of endometrial cancer (EC) are inconsistent. Recent studies of this topic such as PORTEC-3, GOG-258 and GOG-249 investigated the value of adjuvant radiotherapy, adjuvant chemotherapy and combined adjuvant chemoradiotherapy followed by chemotherapy in patients with endometrial cancer and an increased risk of recurrence. With this statement, the Uterus Committee of the Gynaecological Oncology Working Group (AGO) wishes therefore to interpret the new data and discuss them against the background of the new S3 guideline “Diagnosis, treatment and follow-up of patients with endometrial cancer”.

Key words

endometrial cancer - adjuvant therapy - chemotherapy - radiotherapy - recurrence
 

  • References/Literatur

  • 1 Matei D, Filiaci V, Randall M. et al. A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol 2017; 35 (Suppl.) Abstract 5505
    PubMedGoogle Scholar
  • 2 The ASCO Post. ASTRO 2017: GOG-249 confirms adjuvant pelvic radiation as standard of care for high-risk, early-stage endometrial cancer. Online: http://www.ascopost.com/News/58092 last access: 23.01.2018
    PubMedGoogle Scholar
  • 3 De Boer SM, Powell ME, Mileshkin L. et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicenter, randomized, phase 3 trial. Lancet Oncol 2018; 19: 295-309
    CrossrefPubMedGoogle Scholar
  • 4 S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom. Version 1.0 – April 2018 AWMF-Registernummer: 032/034-OL. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ last access: 30.05.2018
    PubMedGoogle Scholar
  • 5 Nout RA, van de Poll-Franse LV, Lybeert ML. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700
    CrossrefPubMedGoogle Scholar
  • 6 Nout RA, Smit VT, Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823
    CrossrefPubMedGoogle Scholar